MEDICAL PHYSICS QUESTIONS FOR MEMBERSHIP EXAMINATION

Edition 13.1

Canadian College of Physicists in Medicine

CANADIAN COLLEGE OF PHYSICISTS IN MEDICINE

LE COLLÈGE CANADIEN DES PHYSICIENS EN MÉDECINE

CCPM Membership Examination **Edition 13.1**

Medical Physics Questions For
Membership Examination
(Edition 13.1)

Questions de Physique Médicale
pour L'Examen d'Admission
(Édition 13.1)

Available from the:

Canadian College of
Physicists in Medicine

Disponible de:

Le Collège canadien des
physiciens en médecine

Mike Sattarivand, PhD, FCCPM, DABR, PEng, CRPA(R)
CCPM Registrar / Greffier du CCPM
registrar@ccpm.ca

Electronic version: ISBN: 0-9684873-3-5

FOREWORD TO THE THIRTEENTH EDITION

This is the thirteenth edition of the published question bank for the Canadian College of Physicists in Medicine (CCPM) membership exam. This is an exam to enable the CCPM to certify that those who pass the four-part written exam and three-part oral exam are competent in their medical physics subspecialty. Combined with credentialing for the exam, this is an exhaustive process into which a candidate is entering.

All question banks underwent significant updates in 2015 and are reviewed annually for suitability of the exam material. The Magnetic Resonace Imaging question bank was further updated in 2016, the Diagnostic Radiological Physics question bank was further updated in 2021. Significant updates to the Nuclear Medicine subspecialty exam were completed in 2023 with several redundant and/or out-dated questions removed and replaced with current/relevant questions; all the questions were reorganized to improve clarity. Smaller updates have been made to the current version of the Radiation Oncology question bank. Note that it is important to ensure that the correct question bank is downloaded when exam preparation begins! Much work has been invested in producing a comprehensive set of questions since 1984 thanks to the hard work of Past Chief Examiners: Ervin B. Podgorsak, Terry M. Peters, Gino Fallone, Ting-Yim Lee, Katharina E. Sixel, Michael D.C. Evans, Robert Corns, Boyd McCurdy, Renée Larouche, Alasdair Syme and Geneviève Jarry and all those who helped them.

A Preparation Guide now exists and is posted on the CCPM website. The Preparation Guide discusses time management strategies and the typical expected length of hand-written answers.

The College wishes to thank Alexandre Bourque, deputy examiner, as well as the many volunteers that help each year. A special thanks goes to Erin Niven and Marjorie Gonzalez who helped with the comprehensive revision of the Nuclear Medicine question bank.

Candidates preparing for their exam who have comments about the question bank are invited to contact me (chiefexaminer@ccpm.ca).

Best of luck to all of the candidates,

Marcus Sonier
Abbotsford, BC, Canada
September 30th 2025

CANADIAN COLLEGE OF PHYSICISTS IN MEDICINE

LE COLLÈGE CANADIEN DES PHYSICIENS EN MÉDECINE

CCPM Membership Examination **Edition 13.1**

SUGGESTED TEXTS FOR PREPARATION OF THE EXAMINATION.

It must NOT be assumed that questions will be based solely on materials from these texts.

A: Radiation Oncology

1. The physics of radiation therapy: F. M. Khan; Williams and Williams, Baltimore.
2. Introduction to radiological physics and radiation dosimetry: P.H. Attix; Wiley, New York.
3. The physics of radiology (Fourth Edition.): H.E. Johns and J.R. Cunningham; Charles C. Thomas, Springfield Ill.
4. Modern technology of radiation oncology: J. Van Dyk (Editor); Medical Physics Publishing, Madison Wisconsin.
5. Radiation physics for medical physicists: E.B. Podgorsak; Springer, New York.
6. Radiation oncology physics: a handbook for teachers and students: E.B. Podgorsak (Editor); IAEA, Vienna.
7. Radiobiology for the radiobiologist: E.J. Hall; Lippincott Williams & Wilkins, New York.
8. ICRP publication 103: 2007 recommendations of the international commission on radiological protection, The International Commission on Radiological Protection; New York, 2007
9. NCRP report 147: Structural shielding design for medical x-ray imaging facilities: National Council on Radiation Protection and Measurements; Bethesda MD.
10. NCRP report 151: Structural shielding design and evaluation for megavoltage X- and gamma-ray radiotherapy facilities: National Council on Radiation Protection and Measurements; Bethesda MD.
11. CPQR Technical Quality Control Guidelines. http://www.cpqr.ca/programs/technical-quality-control/
12, ICRP publication 112: Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies, The International Commission on Radiological Protection; New York, 2009

B: Diagnostic Radiology

1. Physics of radiology (2nd Ed.): A. Wolbarst, Medical Physics Publishing, Madison, WI; 2005
2. Review of Radiological Physics (3rd Ed.): W. Huda, R.M. Slone; Lippincott Williams & Wilkins; 2010
3. Essential Physics of Medical Imaging (2nd Ed.): J.T. Bushberg, J.A. Seibert, E.M. Leidholdt, J.M. Boone; Lippincott Williams & Wilkins; (2001)
4. Medical Imaging Signals and Systems: J.L. Prince, J. Links; 2005
5. Medical Imaging Physics (4th Ed.): W.R. Hendee, E.R. Ritenour; Wiley-Liss; 2002
6. Computed Tomography: Fundamentals, System Technology, Image Quality, Applications (2nd Ed.): W.A. Kalender; Wiley-VCH; 2006
7. Ultrasound Physics and Instrumentation (4th Ed): W.R. Hedrick, D.L. Hykes, D.E. Starchman; Mosby; 2004
8. Guidelines for the safe use of diagnostic ultrasound equipment. Prepared by the Safety Group of the British Medical Ultrasound Society Ultrasound 2010; 18: 52–59.
9. Medical electrical equipment – Characteristics of digital X-ray imaging devices – Part 1: Determination of the detective quantum efficiency. International Standard IEC 62220-1

C: Nuclear Medicine

1. Physics in nuclear medicine (4th Ed): S.R. Cherry, J.A. Sorenson and M.E. Phelps; W.B. Saunders, Philadelphia; 2012
2. Nuclear medicine physics: L.E. Williams (Ed); CRC Press, Boca Raton.
3. The physics of radiology (4th Ed.): H.E. Johns and J.R. Cunningham; Charles C. Thomas, Springfield Ill.
4. Introductory physics of nuclear medicine, R. Chandra; Lea & Febiger, Philadelphia.
5. Radiation detection and measurement, G. F. Knoll; John Wiley and Sons, Third Edition, 2000.
6. Basic science of nuclear medicine, R.P. Parker, P.H.S. Smith, D.M. Taylor; Churchill Livingston, New York.

D: Magnetic Resonance

1. Nuclear magnetic resonance imaging in medicine and biology: P.G. Morris; Oxford University Press, Oxford.
2. Magnetic resonance imaging: physical principles and sequence design, R.W. Brown, YN Cheng, E.M. Haacke M.R. Thompson, and R. Venkatesan, A. John Wiley & Sons, 2014.
3. In vivo NMR Spectroscopy: principles and techniques, R. A. de Graaf, John Wiley and Sons, 2007.
4. Questions and answers in magnetic resonance imaging, Second Edition, A.D. Elster and J. H. Burdette, Mosby, 2001.
5. Handbook of MRI pulse sequences, M. A. Bernstein, K. F. King, and X. J. Zhou, Elsevier Academic Press, 2004.
6. MRI: Basic Principles and Applications (4th Ed.); M.A. Brown, R.C. Semelka; Wiley-Blackwell; 2010
7. Principles of Magnetic Resonance Imaging: A Signal Processing Perspective, Z.P. Liang and P.C. Lauterbur, Wiley-IEEE, 1999

CANADIAN COLLEGE OF PHYSICISTS IN MEDICINE

LE COLLÈGE CANADIEN DES PHYSICIENS EN MÉDECINE

CCPM Membership Examination **Edition 13.1**

Section A: Radiation Oncology Specialty

You will be required to answer **FIVE** questions from Part III and **FIVE** questions from Part IV. Total time to complete these questions is 2.5 hours. Each question is worth an equal percentage, totaling to 100% for each Part.

PART III RADIATION ONCOLOGY

1.
   (a) Define linear attenuation coefficient and energy absorption coefficient for photon beams and describe the difference between the two coefficients.
   (b) Prepare a table showing the relationship between the linear, mass, atomic and electronic attenuation coefficients and show suitable units of these coefficients

2.
   (a) Define and explain the mass energy transfer coefficient and mass energy absorption coefficient.
   (b) Describe and explain the relationship of these two coefficients with the mass attenuation coefficient.
   (c) Express kerma and absorbed dose in terms of the mass energy transfer coefficient and mass energy absorption coefficient, respectively. Consider a mono-energetic beam and a poly-energetic beam.

3.
   (a) List the main photon-matter interactions contributing to the mass attenuation coefficient of an x-ray photon.
   (b) On a graph exhibiting atomic number Z vs log photon energy, sketch two curves, one giving equal probability for photo-electric effect and Compton effect and the other equal probability for Compton effect and pair production.

4.
   (a) Considering photon interactions with matter, describe the photo-electric effect.
   (b) Define and derive the F-factor.

5.
   (a) Considering photon interactions with matter, describe the Compton effect.
   (b) Describe how the average kinetic energy of a Compton recoil electron behave as a function of photon energy, over the range of 10 keV to 30 MeV.

6.
   (a) Considering photon interactions with matter, describe pair production.
   (b) Using $E^2 - p^2c^2 = invariant$, calculate the threshold for pair production.

7. Briefly define or explain:
   (a) Fluorescent yield
   (b) Auger effect
   (c) Internal conversion
   (d) Coster-Kronig effect
   (e) Super Coster-Kronig effect
   (f) Photoelectrons
   (g) Triplet production
   (h) Annihilation photon
   (i) Characteristic radiation
   (j) Rayleigh scattering.

8. Consider the following photon-matter interactions: photoelectric effect; Compton scattering; and pair production.
   (a) For each, state the dependence of the appropriate attenuation coefficient upon the photon energy $h\nu$ and atomic number Z of the medium.
   (b) For each, briefly describe the processes contributing to the transfer of energy from the photon to the medium that follow the interactions.

9.
   (a) State the relativistic equations that represent the conservation of energy and momentum and are used in the derivation of the Compton relationship:

$$\lambda' - \lambda = \lambda_c(1 - cos\theta)$$

   (b) Derive the Compton equation for the energy of the recoil electron.

10.
   (a) Using the Compton relationship, $\lambda' - \lambda = \lambda_c(1 - cos\theta)$, derive expressions for the energy $h\nu'$ of the scattered photon and the kinetic energy T of the recoil electron.
   (b) Show that the energy of the backscattered photon is equal to 255 keV for a high-energy photon.

11. For a photon energy $h\nu$ = 4 MeV incident on lead (Pb), the atomic attenuation coefficients for photo-electric effect ${}_a\tau$, Compton effect ${}_a\sigma$, and pair production ${}_a\kappa$, are:

    ${}_a\tau = 0.567 \times 10^{-24}$ cm^2/atom; ${}_a\sigma = 7.878 \times 10^{-24}$ cm^2/atom; and

    ${}_a\kappa = 5.782 \times 10^{-24}$ cm^2/atom.

    Clearly explaining the steps involved in the calculation, calculate the mass attenuation coefficient μ/ρ, the mass energy transfer coefficient μ_{tr}/ρ, and the mass energy absorption coefficient μ_{ab}/ρ (use the bremsstrahlung fraction g = 0.130, and f_{tr}=0.675 for a 4 MeV photon in Pb).

12. A photon of energy $h\nu$ interacts with lead (Pb):
    (a) Give the general relationship between $h\nu$ and the maximum kinetic energy Emax of the free electron produced through photo-electric effect, Compton effect and pair production.
    (b) Assuming $h\nu$ = 2 MeV, calculate Emax for the three effects.

13. The Klein-Nishina formula relating the Compton differential cross-section $d\sigma_c/d\Omega$ with the photon scattering angle θ is given by:

$$\frac{d\sigma_c}{d\Omega} = \frac{r_e^2}{2} \times \frac{1+\cos^2\theta}{\left[1+\alpha(1-\cos\theta)\right]^2} \times \left\{1 + \frac{\alpha^2(1-\cos\theta)^2}{\left[1+\cos^2\theta\right]\times\left[1+\alpha(1-\cos\theta)\right]}\right\}$$

Where r_e = 2.818 fm is the classical electron radius and $\alpha = h\nu/m_ec^2$ with m_ec^2 = 0.511 MeV.

    (a) Show that for α = 0 and any θ, and that for θ = 0 and any α, $d\sigma_c/d\Omega$ transforms into the classical scattering coefficient per electron, $d\sigma_0/d\Omega$.
    (b) Show that integrating $d\sigma_0/d\Omega$ over dΩ yields $\sigma_0 = 66.5 \times 10^{-30}$ m^2.
    (c) Discuss the effect of electron binding on Compton scattering for low photon energies.
    (d) Sketch examples of Compton scatter-angle cross sections as determined by the Klein-Nishina formula for: 100 kV, 1 MV, 6MV, 15MV.

14.
    (a) Define and explain the stopping powers attributed to collision and radiation losses.
    (b) Describe the difference between the stopping power and linear energy transfer (LET).

15.
    (a) Describe the energy and atomic number dependence of the mass collision stopping power S_{coll} for electrons over the energy range 10 keV to 100 MeV.
    (b) Describe the energy and atomic number dependence of the mass radiative stopping power S_{rad} for electrons over the energy range 10 keV to 100 MeV.
    (c) Sketch on a single graph S_{coll} and S_{rad} for electrons in water and lead in the energy range 10 keV to 100 MeV.

16.
    (a) Using mass collision and mass radiative stopping power relationships with atomic number and energy, describe the optimum design of a bremsstrahlung target for a high-energy linac.
    (b) Describe how target design affects the quality (i.e. percent depth dose) of the x-ray beam for a given incident electron energy?
    (c) Describe how a multi-element target can be used to provide a photon beam of a more desirable spectrum.

17. Briefly define or explain:
    (a) Guard electrodes
    (b) Air-equivalent wall material
    (c) Collection efficiency
    (d) Stem effect
    (e) Build-up cap
    (f) W for air
    (g) Leakage current
    (h) Chamber calibration coefficient
    (i) Ion pair
    (j) Initial and general recombination.

18.
    (a) Draw schematically a parallel-plate (pancake) and a thimble ion chamber, label their main components.
    (b) Describe applications appropriate to a parallel-plate and a thimble ion chamber.

19. Draw a collection efficiency curve for a typical parallel-plate ion chamber irradiated with a continuous photon beam and briefly describe the behavior of the curve as a function of radiation intensity, electrode separation, and photon energy.

20.
    (a) Describe how absolute dosimetry is accomplished with a free-air ion chamber.
    (b) Describe how absolute dosimetry is accomplished with calorimetry.

21. Briefly define or explain:
    (a) Kerma
    (b) Absorbed dose
    (c) Exposure
    (d) Charged particle equilibrium
    (e) Terma
    (f) Bremsstrahlung
    (g) Conversion electrons
    (h) Effective atomic number
    (i) Delta rays
    (j) Fluence.

22.
    (a) Write kerma and absorbed dose in terms of the photon energy fluence and mass attenuation coefficients both for a homogeneous photon beam with energy hν and for a heterogeneous photon spectrum with maximum energy $h\nu_{max}$.
    (b) Briefly describe the Bragg-Gray cavity theory and clearly define the parameters involved.

23.
    (a) Using labeled diagrams, compare an x-ray tube used for therapy (orthovoltage) with an x-ray tube used for diagnosis, clearly indicating the key differences.
    (b) Briefly describe quality control protocols for orthovoltage therapy units.

24.
(a) Sketch a schematic of a diamond detector and describe how it works.
(b) Discuss the circumstances under which a diamond detector should be used for clinical measurements.
(c) What are the advantages of a diamond detector over a conventional thimble ion chamber under these conditions?
(d) How does a diamond detector compare to a diode under these conditions?

25.
(a) Estimate the power delivered to the target of an x-ray tube operated at 100 kVp, 50 mA, 3-phase 12-pulse rectified.
(b) Compare this to the power delivered to the target of a 20 MV linac operated at 50 pps with an electron current pulse width of 7 μs and a height of 50 mA.
(c) Explain the power differences and what are the consequences?

26.
(a) Describe the steps required to produce a clinical electron beam from the electron beam accelerated in the wave guide in a moderne linear accelerators.
(b) Describe how these electrons beams are collimated.

27.
(a) Describe the role and typical properties of flattening filters used in linacs.
(b) Discuss how flattening filter design affects the quality (i.e. percent depth dose) of the x-ray beam for a given incident electron energy.
(c) What is the impact of filter design on dose rate?

28.
(a) Describe how an electron is accelerated to megavoltage energies in a modern linear accelerator.
(b) Describe how a proton is accelerated to megavoltage energies in a modern cyclotron.

29. Give a range of values and units for the following parameters of a typical linear accelerator:
(a) Peak beam current
(b) Average beam current
(c) Modulator pulse width
(d) Peak modulator current
(e) Radiofrequency of operation
(f) Beam current pulse width
(g) Electron gun voltage
(h) Length of accelerating waveguide
(i) Target material and thickness in a 6 MV linac
(j) Electron kinetic energy in the waveguide.

see next page for (k)

(k) Consider the schematic diagram of a linear accelerator below. Match the label blanks of the major components to the following list:

i) Bending magnet
ii) Electron gun
iii) Flattening filter
iv) Focussing coil
v) Ionization chamber
vi) Isocenter
vii) Jaws
viii) Microwave power source
ix) Multi-leaf collimator
x) Primary collimator
xi) Pulsed modulator
xii) Target
xiii) Vacuum pump
xiv) Waveguide.



30.
(a) Explain why the output (cGy/MU), both in air and in phantom, of a linear accelerator changes with field size.
(b) Sketch a graph of relative output in air (e.g. S_c) vs. field size for typical 6 MV and 18 MV photon beams, ignoring contaminant electrons.
(c) Sketch a graph of relative output in phantom (eg. $S_{c,p}$) vs. field size for typical 6 MV and 18 MV photon beams, ignoring contaminant electrons.
(d) What is the effect of increasing photon energy on the relationship between these factors and field size?
(e) What is the challenge when measuring relative output in air for a high energy beam?

31. Briefly define or explain:
(a) Gamma analysis
(b) DTA
(c) Flatness
(d) Symmetry
(e) Tolerance level
(f) Action level
(g) Picket fence
(h) Winston-Lutz test
(i) Star shot test
(j) Acceptance testing vs commissioning

32. Acceptance testing of a linear accelerator with multileaf collimation and electronic portal imaging can be classed into several broad categories. Five of these categories are safety, mechanical, dosimetric, imaging, and multi-leaf collimator.
(a) Within each catagory, give two examples of a measurement or test, as well as the associated acceptable tolerance specification.
(b) Discuss the rationale for the use of both tolerance and action levels.

33.
(a) What are the typical model parameters used by a radiation therapy treatment planning system which uses a model-based, patient dose calculation algorithm?
(b) Describe the measurements and extent of data required to generate a new beam model in the treatment planning system.
(c) How are the beam model parameters used in three-dimensional patient dose calculations and monitor unit calculations?

34.
(a) Describe a common hand-calculation formalism for verifying the monitor units of a 3D conformal treatment plan developed on a treatment planning system. Assume an SAD-setup photon treatment and use of a tissue-phantom ratio table. Explain all parameters involved.
(b) Explain the concepts of 'equivalent field size' and 'effective radiological pathlength' in the context of hand calculations for verifying monitor units.
(c) Briefly describe some general considerations if one wanted to modify the technique to apply to IMRT fields.

35.
(a) Describe in detail a protocol for clinical reference dosimetry for an 18 MV beam in a medical linear accelerator using a cobalt-60 calibrated ionization chamber. Include a detailed description of the necessary equipment, measurement geometry and conditions, as well as the medium in which the measurement must be made.
(b) Give the equation used and fully define each parameter.
(c) Define how beam quality is specified including a description of the necessary equipment, measurement geometry, and conditions.

36. Define the following functions used in manual radiation oncology dose calculations, sketch the relevant geometry, and clearly state what beam parameters the functions are influenced by:
(a) percentage depth dose (PDD)
(b) tissue-maximum ratio (TMR) and tissue-phantom ratio (TPR)
(c) off-axis ratio (OAR)
(d) wedge factor (WF)
(e) zero-area percentage depth dose.

37.
(a) Sketch a PDD for a 6 MV beam with flattening filter, for 100 cm SSD and 10×10 cm^2 field.
(b) Explain why the PDD function changes with depth (beyond D_{max}).
(c) Explain the PDD dependence on beam energy.
(d) Explain the PDD dependence on field size.
(e) Explain the PDD dependence on SSD.

38.
(a) For a large field, 6 MV beam with flattening filter, explain how and why the beam profile changes with depth.
(b) When a beam of megavoltage photons irradiates a phantom surface, there is dose delivered to the superficial layers of the patient, mainly due to contaminant electrons. Describe the shape of this contaminant electron dose contribution as a function of depth.

39. Describe the following three methods for tissue heterogeneity corrections in dose calculations with photon beams, and give the advantages and disadvantages of each:
    (a) a simple hand calculation approach;
    (b) a pencil-beam dose kernel superposition algorithm approach; and
    (c) a point-dose kernel superposition algorithm approach.

40. Monte Carlo (MC) dose calculation engines are available for many treatment planning systems.
    (a) Discuss the advantages of the MC dose engine over other methods.
    (b) Briefly explain how a particle history is calculated from a collection of pseudo-random numbers.
    (c) Briefly explain how a dose distribution is obtained from a collection of particle histories.

41. The Klein-Nishina formula relating the Compton differential cross-section $d\sigma_c/d\Omega$ with the photon scattering angle θ is given by:

$$\frac{d\sigma_c}{d\Omega} = \frac{r_e^2}{2} \times \frac{1+\cos^2\theta}{\left[1+\alpha(1-\cos\theta)\right]^2} \times \left\{1 + \frac{\alpha^2(1-\cos\theta)^2}{\left[1+\cos^2\theta\right]\times\left[1+\alpha(1-\cos\theta)\right]}\right\}$$

    where $r_e = 2.818$ fm is the classical electron radius and $\alpha = h\nu/m_e c^2$ with $m_e c^2 = 0.511$ MeV.

    (a) Describe how this equation could be used by a Monte-Carlo simulation program to model a Compton interaction in a medium. Include the role of a random number generator and the sampling process in your description.
    (b) Describe how the program would decide the trajectory and energy of an electron produced in the interaction.

42. Dose distributions calculated using a Monte Carlo (MC) dose engine are subject to statistical noise.
    (a) Why is statistical noise present in a MC dose distribution?
    (b) Write expressions showing how the relative noise depends upon:
        i. The number of particle histories;
        ii. The dose-grid voxel size;
        iii. The dose as a percentage of prescription dose; and
        iv. The MC simulation time.

    (c) Sketch a typical cumulative dose volume histogram (DVH) for a planning target volume prescribed to 70 Gy with minimum dose of 67 Gy and maximum dose of 72 Gy. On the same graph sketch the DVH that would be obtained using a MC dose engine with relative statistical noise of 10%.

43. Briefly define or explain:
    (a) Kinetic energy of electrons
    (b) Contaminant electrons
    (c) R_{50} of an electron beam
    (d) Practical range of electrons
    (e) Stopping power ratio
    (f) Cerenkov radiation
    (g) Fricke dosimetry
    (h) Radiation chemical yield
    (i) Thermal defect
    (j) Heat capacity

44.
    (a) Sketch percentage depth doses for a typical 10×10 cm^2 electron beam, SSD 100 cm, with initial kinetic energies of 6, 12, and 18 MeV.
    (b) Describe, with the aid of a sketch, the shape of the isodose distribution for a 12 MeV electron beam.

45.
    (a) Sketch percentage depth doses for a 15 MeV electron beam for field sizes 3x3 cm^2, 10x10 cm^2 and 20x20 cm^2. Explain the differences and/or similarities of these three curves.
    (b) Briefly describe what must be considered when electron fields are shaped to substantially reduce their size.

46.
    (a) Describe the protocol for absorbed dose measurement in an 18 MeV electron beam with a dose calibrated ionization chamber.
    (b) Give the equation used and fully define each parameter.
    (c) Include a description of the measurement geometry and appropriate phantom material.
    (d) How is beam quality specified?

47.
    (a) Describe the basic physics behind the Optically Stimulated Luminescence (OSL) process.
    (b) Show schematically a typical apparatus for OSL measurements. Clearly label the components.

48. Briefly define or explain:
    (a) Pre-irradiation annealing
    (b) Post-irradiation annealing
    (c) Glow curve (thermogram)
    (d) Recombination centre
    (e) Storage trap
    (f) Activation energy
    (g) Supralinearity
    (h) Infrared emission of the planchet
    (i) Randall-Wilkins model
    (j) Optically stimulated luminescence.

49.
(a) Compare thermoluminescent dosimeters with optically stimulated luminescence dosimeters and state an advantage and disadvantage for each one.
(b) Describe the use of thermoluminescent dosimetry or optically stimulated luminescence dosimetry for patient dose monitoring in external beam therapy.
(c) Describe calibration and handling techniques for one of these techniques. Include a description of the relevance of the measured values when attempting to validate doses calculated for a treatment plan.
(d) Explain the rationale for using on-board imaging for patient dose monitoring.

50.
(a) Name four relative dosimetry techniques other than thermoluminescent or optically stimulated luminescence dosimetry.
(b) Briefly describe their main characteristics and applications.
(c) Describe advantages and disadvantages.

51. There are various approaches used in interstitial and intracavitary brachytherapy.
(a) Describe high-dose rate (HDR) and seed-implant brachytherapy dose delivery methods, including the mechanism of dose delivery and common radioisotopes used.
(b) Give a clinical application (anatomy and typical dose) for each.
(c) Explain the advantages offered by remote afterloading compared to manual afterloading, and by manual afterloading compared to insertion of active needles.

52.
(a) What are the properties of an ideal brachytherapy radioisotope?
(b) Describe two brachytherapy sources: one commonly used in remote afterloading systems and one used for manual loading techniques. Include physical construction, and radiation parameters such as half-life, typical activity, energy, and air kerma rate constant.
(c) Describe a common clinical use of each source. Specify treatment anatomy, planning method and safety considerations.

53.
(a) Describe a practical method of calibrating an HDR brachytherapy source after its installation in a clinical remote afterloader. Specify all equipment used.
(b) Explain how an absorbed dose distribution for a typical brachytherapy source is determined.

54.
(a) What imaging modalities are recommended for brachytherapy planning, and which is considered the gold standard?
(b) What are typical dose-fractionation schemes for the external beam and HDR brachytherapy components of a cervix treatment? Discuss a formalism to combine and evaluate the overall dosimetry.
(c) Discuss the Overall Treatment Time (OTT) on local control in cervical cancer treated with EBRT + brachytherapy and state general recommendations for optimizing OTT.

55. With respect to permanent seed implantation for the treatment of early stage prostate cancer:
(a) Briefly outline the clinical workflow of a patient who will undergo this treatment, beginning with initial assessment, through to post implant treatment evaluation.
(b) Describe the steps and tools required for the recommended quality assurance of the radioactive seeds prior to implantation.
(c) Describe the steps and tools required for the recommended quality assurance of a trans-rectal ultrasound system used for image guidance during the implant.

56. With respect to brachytherapy dose calculations:
(a) Describe the commonly used dose calculation formalism giving definitions and explanations for all quantities.
(b) Describe the conditions under which this formalism can fail to accurately calculate dose.

57. With respect to HDR brachytherapy for prostate cancer:
(a) Describe how treatment planning is performed.
(b) Describe how the treatment is delivered.
(c) Describe four differences in the radiation protection concerns for HDR prostate treatment versus permanent seed implantation.
(d) Describe the differences in eligibility and selection for patients undergoing HDR brachytherapy versus permanent seed implant.

58.
(a) Describe in detail a standard radiation treatment of the breast or chest wall, including the regional lymph nodes. Include considerations of protecting organs at risk, achieving dose homogeniety in three dimensions, and problems associated with beam junctioning.
(b) State two commonly used total dose and fractionation schemes.

59. Consider the planning, treatment and verification of prostate irradiation using external beam radiotherapy.
    (a) Define tumor and target volumes using ICRU 50 and ICRU 62 terminology and define specifically what these refer to in prostate external beam irradiation.
    (b) State two commonly used total dose and fractionation schemes.
    (c) Describe a typical modern treatment technique, including elements of simulation, treatment planning and treatment delivery.
    (d) Describe 3 possible methods of assessing patient position during treatment, including how they are specifically used in prostate treatment.
    (e) List two organs at risk and for each list tolerance doses and associated toxicity (please indicate the sources (institutional, trial, literature) used to obtain those values)

60. According to ICRU, the planning target volume (PTV) is a geometric concept that ensures that the prescribed dose is actually delivered to the clinical target volume (CTV). A number of different methods have been proposed to define the magnitude of the CTV to PTV margin. One approach, based on probability distributions, is to distinguish between the random and systematic errors that contribute to geometric deviations. When this approach is employed, the commonly used equation is to define the PTV margin is:

$$PTV = 2.5\Sigma + 0.7\sigma$$

where Σ is the standard deviation of systematic errors and σ represents the standard deviation of random errors. This equation ensures a minimum dose to the CTV of 95% of the prescription dose in 90% of patients, assuming a penumbra width of 3.2 mm.

    (a) A number of simplications are assumed in deriving this model. Briefly discuss four of them.
    (b) Describe how a dose distribution is modified by random and systematic errors.
    (c) For an intra-cranial (ie. brain) tumour treatment, list three sources of geometric deviations and briefly discuss their relative contributions to Σ and σ.
    (d) Briefly discuss why this equation does not apply to the determination of a planning organ at risk (PRV) margin.

61.

(a) Describe the rationale for total body irradiation (TBI) prior to bone marrow transplantation for leukemia.
(b) Describe two techniques for TBI using a linear accelerator.
(c) Give the dose regimen and two dose constraints for organs at risk.
(d) Describe the medical problems encountered during or after TBI.
(e) Describe the theoretical advantages and disadvantages of delivering the dose in a single fraction as compared to multiple fractions.
(f) Briefly describe dosimetric measurements that must be performed before a standard linear accelerator can be used for TBI.

62.

(a) Describe the rationale for using adaptive radiotherapy
(b) Identify two types of cancer that benefit from adaptive radiotherapy and explain the reasons for this benefit.
(c) Describe two methods that are used to perform adaptive treatments
(d) Briefly discuss two disadvantages of using adaptive radiotherapy

63.

(a) State two types of cancer that can benefit from the management of respiratory motion and explain the rational for using it.
(b) Describe two methods that are used for the management of respiratory motion.
(c) Explain the impact of those methods on patient preparation, CT-scan protocol and treatment planning.

64.

(a) Describe in detail the required changes to, and measurements on, a standard linear accelerator before it can be used to deliver total skin electron irradiation (TSEI).
(b) Describe one treatment technique currently employed for TSEI.
(c) State typical doses and fractionations used.

65.

(a) List three cranial disease sites or indications for which stereotactic radiosurgery (SRS) is a treatment of choice, and provide a typical dose and fractionation scheme for each.
(b) List three extra-cranial disease sites or indications for which stereotactic body radiation therapy (SBRT or SABR) is a treatment of choice, and provide the typical dose and fractionation scheme for each.
(c) Describe the advantages and disadvantages of using stereotactic techniques (SRS/SBRT) versus conventional (ie. non-stereotactic) treatments.
(d) Compare the margin requirements of stereotactic techniques to conventional treatments, and describe the techniques used to achieve tighter margins in SRS/SBRT.

66.

(a) Describe three major platforms for performing stereotactic radiosurgery (SRS) and/or stereotactic body radiation therapy (SBRT).
(b) How do commissioning and quality assurance requirements differ for a linac used for SRS/SBRT compared to a linac used for conventional treatments?

67.

(a) Briefly describe the basis of helical radiotherapy (Radixact [Tomotherapy]) and explain how intensity modulation is achieved throughout the target volume.
(b) Sketch and describe the main components of a helical radiotherapy unit.
(c) Describe two issues in beam dosimetry that may be more challenging with a helical radiotherapy unit compared to conventional linac dosimetry.
(d) Discuss one treatment site in which helical radiotherapy has a clear advantage over conventional linac dosimetry.

68.

(a) State the rationale for the use of protons for cancer therapy.
(b) Sketch the relative dose versus depth curve for a 120 MeV proton beam. Show how multiple modulated beams can be combined to produce a more clinically useful depth dose distribution.
(c) Describe the range of energies that are appropriate for proton therapy.
(d) Describe two methods for producing clinically useful large laterally uniform fields from the narrow proton beams produced in a typical proton accelerator.

69.
(a) Discuss the rationale for the use of chemotherapy in the treatment of cancer.
(b) Provide two examples of types of cancers that receive chemo and radiation and discuss how these regimen were adopted by mentioning relevant studies.
(c) What considerations must be taken into account when implementing a chemoradiation treatment protocol?

70. Define or explain, using sketches where applicable, the following:
(a) 4DCT
(b) Cone-beam CT (CBCT)
(c) CT number vs electron density
(d) Digitally reconstructed radiographs (DRR)
(e) Beam's-eye view (BEV)
(f) Surface Guided Radiotherapy (SGRT)

71. Fusion, registration and deformable registration of imaging modalities:
(a) Describe three different uses of image fusion in radiation therapy
(b) Briefly discuss how does image fusion impact the quality of treatments
(c) Briefly discuss the rational for using deformable image registration (DIR) compared to rigid registration

72.
(a) Explain the principle and benefits of respiratory gating in external beam radiation therapy.
(b) Describe tumor tracking techniques and how they differ from gating.
(c) Give one limitation for each technique.

73. Compare the use of CT and MRI in radiotherapy treatment planning with reference to resolution, contrast, spatial and geometric uniformity of the images and their ability to:
(a) Locate bony landmarks;
(b) Delineate tumour volumes and critical organs (describe tumour extent);
(c) Give information for tissue inhomogeneity corrections.

74.
(a) Describe a typical PET/CT scanner system.
(b) Describe the main tracer used, it's biological basis for PET imaging, and applicability for oncologic imaging.
(c) Describe two common clinical disease sites where PET/CT systems are used in a radiation oncology program.
(d) What technical considerations need to be made to make the most effective use of a PET/CT system for a radiation oncology department (as opposed to a radiology department)?

75. In relation to inverse planning to achieve optimal beam fluences for modulated radiation therapy (IMRT or VMAT), explain:
(a) objective functions,
(b) dose objectives,
(c) dose constraints,
(d) typical non-stochastic optimization methods,
(e) typical stochastic optimization methods.

76. Describe the following techniques for delivering modulated treatments, including how modulation is accomplished and comparative advantages and disadvantages:
(a) static or segmental multileaf collimator (SMLC or 'step and shoot'),
(b) dynamic multileaf collimator (DMLC or 'sliding window'), and
(c) volumetric modulated arc therapy (VMAT).

77. Describe the following techniques for patient-specific quality assurance of modulated treatments including comparative advantages and disadvantages:
(a) phantom-based measurement (with ion chamber(s)/film(s)),
(b) 2D ion chamber/diode arrays,
(c) EPID,
(d) independent MU check.

78. How does an Oncology Information Systems (OIS) work as an integrated part of a radiation-oncology department?
Explain the purpose and use of:
(a) Firewall
(b) Checksum
(c) DICOM
(d) PACS

79.

(a) State the rationale for using orthovoltage photons versus electrons, for cancer therapy;
(b) Sketch percentage depth dose curves for 100 kVp and 270 kVp, assuming FSD=30 cm and appropriate filtration for each beam;
(c) Describe the main treatment sites where orthovoltage photon beams are typically considered.
(d) Briefly describe the protocol for absolute dose measurements in an orthovoltage beam with a calibrated ion chamber. State the relevant equation and define the terms.

80. There are multiple volumetric CT-based systems that can be used in image guided radiation therapy. These include kV cone beam CT, kV fan beam CT and MV fan beam CT.

(a) For a standard pelvis scan, provide approximate dose values for each modality, specifying the dose metric used. Briefly describe the rationale for the differences.
(b) Briefly discuss why there are differences in spatial resolution and contrast amongst the different modalities. The answer should include at least three reasons for the differences in spacial resolution and three reasons for differences in contrast.
(c) Briefly discuss differences in the susceptibility to and the effects of motion artifacts between the different modalities.

81.

(a) Explain the different phases of a clinical trial.
(b) What is the role of a Medical Physicist in a radiotherapy clinical trial?
(c) Name two clinical trials for lung cancer.

PART IV RADIATION ONCOLOGY

1. Briefly define or explain:
   (a) Stopping power
   (b) Half-value layer (HVL)
   (c) Tenth-value layer (TVL)
   (d) Air kerma
   (e) Absorbed dose
   (f) Equivalent dose (H_T)
   (g) Effective dose (E)
   (h) Radiation weighting factor (w_R)
   (i) Tissue weighting factor (w_T).
   (j) Annual limit on intake (ALI).

2.
   (a) Describe the concept of linear energy transfer (LET), and provide its units
   (b) How is LET related to biological effectiveness?
   (c) How does LET vary with the type and energy of charged particles? Provide some examples.
   (d) How does LET vary with depth in a medium in which particles are slowed down?

3.
   (a) Considering the linear quadratic model, describe the effect of linear energy transfer (LET) on the cell survival curve.
   (b) Relative to the cell survival curve, describe the relationship between LET and relative biological effectiveness (RBE)?

4.
   (a) Define the oxygen enhancement ration (OER) and explain how the presence of oxygen modifies radiation response.
   (b) What is a typical value of OER for a dose of 200 cGy from X-rays?
   (c) Sketch OER as a function of LET.

5.
   (a) Briefly describe the evidence upon which the ICRP Publication 103 values of radiation weighting factors (w_r) are based.
   (b) What are the radiation weighting factors for photons, electrons, protons, and alpha particles?
   (c) Briefly explain why the radiation weighting factor for neutrons is a continuous function (instead of a single value)?

6. In the context of radiation detection, briefly define or explain:
   (a) Photo-peak
   (b) Dynode
   (c) Signal saturation
   (d) Compton edge
   (e) Electronic avalanche
   (f) Space charge
   (g) Quenching
   (h) Coincidence loss
   (i) Paralyzable system
   (j) Non-paralyzable system.

7. Ionization chambers, proportional counters and Geiger-Müeller counters are all gas filled radiation detectors.
   (a) Sketch a graph illustrating the operation of a gas filled detector plotting pulse amplitude against applied voltage. Indicate the regions on this graph which define the different detector types.
   (b) Discuss advantages and disadvantages of these detectors in the the field of radiation protection.
   (c) Give an example of an application for each type of detector (ie. ionization chamber, proportional counter, and G-M counter).

8. In the context of radiation protection:
   (a) Draw a diagram showing the design of an ionization chamber and its associated circuitry when used with an electrometer. Identify the primary components and briefly describe their purpose.
   (b) Describe the use of a portable ionization chamber for the radiation protection survey of a linear accelerator bunker.

9. Describe:
   (a) A proportional counter;
   (b) The energy discrimination ability of a proportional counter;
   (c) How to calibrate a proportional counter as a tissue equivalent detector.

10. Describe:
   (a) A Geiger-Mueller (G-M) counter;
   (b) How to distinguish between beta and gamma radiation with a G-M counter; and
   (c) How to determine source strength of a beta emitter with a G-M counter.

11.
(a) Considering neutron interactions, briefly define or explain:
  i. thermal neutrons;
  ii. elastic collision; and
  iii. recoil proton.
(b) Describe two ways of measuring neutrons in the presence of X- or gamma rays.
(c) With respect to the measurement of neutrons using a BF_3 detector briefly define or explain:
  i. The interactions of thermal neutrons with BF_3
  ii. The physical design characteristics of a BF_3 detector
  iii. A method to measure the fast neutron component of a neutron field
  iv. The reporting of equivalent dose rate from a neutron field

12. In the context of radiation safety measurements:
(a) Briefly define or explain:
  i. standard deviation and standard error;
  ii. precision and accuracy of measurement;
  iii. relative and absolute uncertainty.
(b) Describe the effect of background radiation on the precision of radiation measurements.

13. Give the annual effective dose limits for stochastic effects recommended by ICRP Publication 103 for both occupational and public exposures.
(a) Explain how effective dose is determined when the whole body is irradiated non-uniformly with a mixed radiation field.
(b) Give four examples of tissue weighting factors.

14. The Canadian Nuclear Safety Commission specifies effective dose limits for three categories of people:
  (i) Nuclear energy worker;
  (ii) Pregnant nuclear energy worker; and
  (iii) A person who is not a nuclear energy worker.

(a) State the effective dose limits for the three groups and compare them to the effective dose from natural background. Include the time periods for which the limits apply.
(b) Comment on how emergencies may affect dose limits.
(c) What has been the largest driver of increased exposure to the public over the last 30 years?
(d) Describe three principles that can be followed to decrease the population risk for both NEWs and the public.

15.
(a) The Canadian Nuclear Safety Commission specifies equivalent dose limits. List the organs or tissues for which an equivalent dose limit exists, give the magnitude of the equivalent dose limit in mSv, and the time period for which this limit applies, for:
   i. Nuclear energy worker;
   ii. Any other person.

(b) Briefly describe the five steps the Canadian Nuclear Safety Commission requires a licensee to perform when the licensee becomes aware that an organ or tissue may have exceeded an applicable dose limit.

16. Briefly define or explain:
(a) Detriment in a population
(b) Stochastic effect
(c) Deterministic effect
(d) Linear energy transfer (LET)
(e) Relative biological effectiveness (RBE)
(f) Oxygen enhancement ratio (OER)
(g) Cancer stem cells
(h) Body burden
(i) Therapeutic ratio
(j) Free radicals.

17. Cardiac Implantable Electronical Devices (CIED) are treated with caution in radiation therapy:
(a) What CIED characteristics or patient information are relevant for treatment design?
(b) How does radiation affect these devices and what are the potential issues for the patient?
(c) What is the typical dose tolerance for CIED?
(d) What are the different strategies we could use in order to safely deliver dose in the presence of a CIED.

18. In the context of radiation protection at a radiotherapy facility, briefly define or explain:
(a) Primary barrier
(b) Leakage radiation
(c) Scatter radiation
(d) Secondary barrier
(e) Use factor U
(f) Workload W
(g) Occupancy factor T
(h) Beam stopper
(i) Tenth-value layer at equilibrium (TVL_e)
(j) ALARA principle.

19. Consider a typical radiation oncology bunker, housing an isocentrically mounted 6MV linear accelerator.
(a) Give typical values for W, T and U, as well as thicknesses for primary and secondary barriers.
(b) Explain how the barrier thicknesses are calculated in NCRP 151.
(c) Explain how the ALARA principle is taken into account when a room is designed.

20. Describe briefly why it is difficult to obtain accurate information on the biological effects on humans at low doses (e.g. 10 mGy) of low-LET ionizing radiations, especially if the dose is accumulated over a long period of time.

21.
(a) Describe the concepts of excess absolute risk (EAR) and excess relative risk (ERR) in ICRP 103.
(b) Describe the steps ICRP 103 uses to move from the concepts of EAR and ERR to tissue weighting factors.

22. Define the following:
(a) Early effects
(b) Late effects
(c) Linear quadratic model
(d) T_{pot}
(e) T_{delay}
(f) α parameter of the LQ model
(g) β parameter of the LQ model
(h) Accelerated repopulation
(i) Sublethal damage repair
(j) Dose-rate effect

23.
(a) Describe the usefulness and limitations of the linear-quadratic model in comparing different dose-time-fractionation schemes used in radiotherapy:
(b) Using the linear-quadratic model, with *d* = "*dose per fraction*", and *n* = "*number of fractions*", derive the equation for biological effective dose:

$$\frac{E}{\alpha} = dn\left(1+\frac{d}{\alpha/\beta}\right)$$

24.
(a) In terms of the linear-quadratic model, describe the range of the α/β ratio for early and late responding tissues and give two examples each of early and late responding tissues.
(b) With respect to the linear-quadratic model, define and compare the concept of dose in Gy, and $Gy_{\alpha/\beta}$.
(c) Compare a conventional therapy regimen of 30 fractions of 2 Gy at one fraction per day, 5 days per week with that of a hyperfractionation schedule of 70 fractions of 1.1 Gy given at 2 fractions per day 6 hours apart, 5 days per week. Assume $\alpha/\beta = 2$ for late effects, and $\alpha/\beta = 10$ for early or tumour effects. Express the results in Gy_2 and Gy_{10}, and compare the two regimens in terms of impact on tumour response and normal tissue late response.

25. A cancer center has decided to close for a summer break of 10 working days. The radiation oncologist has concerns that this may effect radiotherapy outcome.
    (a) Give the equation using the linear quadratic model which may be used to assess the effects of this closure, including a term for tumour stem cell proliferation.
    (b) Assume Hodgkins lymphoma has a T_{pot} of 5 days and glioma a T_{pot} of 30 days. Calculate the effective dose reduction factor for each of these tumours in terms of Gy_{10}. Assume fractionation for the lymphoma is 1.8Gy/fraction for 20 fractions and for the glioma is 1.8 Gy/fraction for 28 fractions. Also assume α=0.3 Gy^{-1} for both.
    (c) Describe whether closure of the clinic is advisable for either of these tumours.

26. Briefly define or explain the following concepts of tumour radiobiology:
    (a) Radiobiological hypoxia
    (b) Labeling index
    (c) Radioprotector
    (d) Spheroid model
    (e) Hyperfractionation
    (f) Hypofractionation
    (g) Anoxic radiosensitizer
    (h) S-phase of cell cycle
    (i) M-phase of cell cycle
    (j) LD_{50}.

27.
    (a) Sketch a model of a solid tumor at various stages of its growth, showing capillaries and areas of hypoxia and necrosis.
    (b) What is the concentration of oxygen below which cells are generally considered to be radiobiologically hypoxic?
    (c) What is the diffusion distance of oxygen in tissue?
    (d) Describe and contrast chronic hypoxia and acute hypoxia.

28. Describe the “4 R's” in radiobiology and explain their role in fractionated radiotherapy.

29. Cataracts may be classified as delayed somatic effects of radiation.
    (a) Describe how cataracts develop in the lens of the eye as a result of exposure to ionizing radiation.
    (b) Describe the time/dose relationship for cataract production by x- or gamma-rays.
    (c) Describe the threshold for cataract formation and the effect of total dose on the latent period for cataract induction.
    (d) Compare the incidence of cataract following neutron irradiation with that observed following X- or gamma irradiation.

30.
(a) Briefly describe the molecular structure of DNA.
(b) Briefly describe the direct and indirect effects of ionizing radiation on DNA.
(c) Referring to ICRP 103, comment on the risk of cancer for nuclear energy workers working in the hospital environment who receive their yearly legal limit each year during a 25 year career. Clearly state all assumptions.

31.
(a) Describe the genetic effects of radiation in humans and explain the use of the concept of the doubling dose as the unit of measurement of the radiation effect.
(b) List the main sources of ubiquitous background radiation and medical radiation, and the effective dose per individual they contribute to the general population, as estimated in NCRP 160.
(c) What is the genetic effect of ionizing radiation in the occupational dose range?

32. Describe the effect of ionizing radiation on the embryo and the fetus during the different stages of pregnancy.

33. Describe the acute effects of whole-body irradiation and give the radiation dose that would produce such effects.

34.
(a) Describe a typical cell survival curve, clearly define its parameters and describe its shape.
(b) With the aid of a sketch, describe and compare typical cell survival curves for aerated cells vs hypoxic cells irradiated with 250 kVp x-rays.
(c) What is the oxygen enhancement ratio for protons and neutrons?

35.
(a) Describe four security measures required for an HDR brachytherapy program using Ir-192.
(b) An HDR source fails to retract into the safe position during a treatment. Describe the emergency response protocol to follow including staff actions, patient management and post-event regulatory reporting.

36.
(a) Identify the regulatory bodies that oversee the use, possession, and transport of HDR brachytherapy sources in Canada. Briefly describe their main roles.
(b) Describe the packaging and labelling requirements for transporting an HDR Ir-192 source.
(c) Discuss documentation and administrative controls required for an HDR source shipment.

37. The QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) effort seeks to provide standardized, outcome-based tolerances for a variety of organ's at risk.
    (a) Describe the general methodology employed in QUANTEC.
    (b) Describe the limitations of QUANTEC
    (c) Describe the lessons learned by the QUANTEC effort.

38. For each of the following events described in ICRP 112 Accidental Exposures with New Technologies in External Beam Radiation Therapy, describe i) the main cause(s) that led to the error, ii) the clinical impact of the error, and iii) two strategies that may reduce the risk of this type of event.
    (a) Case 1. Inappropriate detector size used when commissioning micro-MLCs (Toulouse)
    (b) Case 4. Monitor Unit calculation for the wrong type of wedge. (Epinal);
    (c) Case 5. Computer crashes and the loss of data in IMRT planning. (New York State)
    (d) Case 9. Incorrect manual transfer of treatment parameters. (Glasgow).

39.
    (a) Describe how a Failure Modes and Effects Analysis could be performed in the radiotherapy setting.
    (b) For each of the following Failure Modes, identify one possible cause and suggest, with reasons, values for Frequency (F), Severity (S) and Detectability (D) parameters
        i. incorrect vertebra matched during the image guidance procedure for a spinal SBRT treatment;
        ii. incorrect set of objectives and constraints used in plan optimization; and
        iii. bolus missed on one fraction out of twenty.
    (c) For each case in (b) above, what preventative measures could be employed to decrease D, (i.e. increase the detectability of the error before it reaches the patient)?

40. You are asked to oversee design and installation of a facility for an 18 MV linear accelerator to be used in the photon (18 MV) and electron mode (6 MeV to 21 MeV).
    (a) Discuss which regulatory agency(ies) and which regulation(s) must be considered and adhered to.
    (b) Describe the CNSC licensing requirements over the lifetime of the linear accelerator.
    (c) What is the purpose of a lifecycle license?
    (d) List design considerations that might be imposed by special techniques such as intraoperative radiotherapy, total body electron irradiations, and total body photon irradiations.



41. An 18 MV linac (SAD 100 cm, maximum field size at isocentre of 40x40 cm^2) is to be installed in a stand-alone facility on the ground floor as shown in the sketch (not to scale). There are no rooms above the linac. The operator console is at location A, office space is at location B, the treatment room door is shown and all other adjacent areas are unoccupied.
    (a) Discuss the design criteria for a treatment room door and clearly indicate the typical materials and approximate material thicknesses used.
    (b) Clearly describe and identify the location of all safety accessories both inside and outside the room.
    (c) Discuss the area radiation safety survey, and list the equipment to be used. Indicate typical measured values you might expect to measure at points A, B and C (both for door open and door closed), and indicate the nature and location of any warning signs.



42. A dual-energy linac (6 and 18 MV, SAD 100 cm, maximum field size at isocentre of 40x40 cm^2) is to be installed in a stand-alone facility on the ground floor as shown in the sketch (not to scale). There are no rooms above the linac. The operator console is at location A, office space is at location B and all other adjacent areas are unoccupied. Assume that 20 patients are treated per day using 6 MV IMRT, and 10 patients are treated per day using conventional 18 MV techniques. Using the methodology suggested by NCRP 151, and clearly stating all assumptions:
    (a) Calculate the primary barrier thickness (t_A) at Point A for regular concrete.
    (b) Calculate the thickness of the secondary barrier (t_B) at point B for regular concrete. Assume the barrier thickness designed for leakage radiation is sufficient to also shield for scatter (as per NCRP 151).